OCULAR SURFACE AND GLAUCOMA DRUGS.

  • Department of Ophthalmology (Head: Prof. A. Caporossi) ? Catholic University of Roma ? Rome ? ITALY ? EU.
Crossref Cited-by Linking logo

  • Abstract
  • Keywords
  • References
  • Cite This Article as
  • Corresponding Author

This is a short communication about the use of antiglaucoma drugs and their impact on the ocular surface of glaucomatous patients. The Author stressed the influence of the evolution of topical antiglaucoma drugs and their preservatives on the ocular surface in the last five years.

  1. Garcia-Feijoo J., Munoz-Negrete F.J., Hubatsch D.A., Rossi G.C.(2016). Efficacy and tolerability of benzalkonium chloride-free travoprost in glaucoma patients switched from benzalkonium chloride-preserved latanoprost or bimatoprost. Clin. Ophthalmol. Oct 21; 10: 2085-2091.
  2. Giuffre? I.(2014). Ocular surface disease index in glaucomatous patients treated with bimatoprost. Open J. Ophthalmol., 4: 36-39.
  3. Konstas A.G., Boboridis K.G., Kapis P. et al.(2017). 24-hour efficacy and ocular surface health with preservative-free tafluprost alone and in conjunction with preservative-free dorzolamide/timolol fixed combination in open-angle glaucoma patients insufficiently controlled with preserved latanoprost monotherapy. Adv. Ther.Jan; 34 (1): 221-235.
  4. Labbe? A., Alalwani H., Van Went C. et al.(2012). The relationship between subbasal nerve morphology and corneal sensation in ocular surface disease. IOVS Jul. 24; 53 (8): 4926-4931.
  5. Mastropasqua R., Agnifili L., Fasanella V. et al.(2016). In vivo distribution of corneal epithelial dendritic cells in patients with glaucoma. IOVS Nov. 1; 57 (14): 5996-6002.
  6. Peace J.H, Ahlberg P., Wagner M. et al.(2015). Polyquaternium-1-preserved travoprost 0.003% or Benzalkonium chloride ? preserved travoprost 0.004% for glaucoma and ocular hypertension. Am. J. Ophthalmol.; 160(2): 266-274.
  7. Perez-Bartolome? F., Martinez-de-la-Casa J.M., Arriola-Villalobos A.(2017). Ocular surface disease in patients under topical treatment for glaucoma. Eur. J. Ophthalmol. 2017 May 10 (Epub ahead of print).
  8. Quaranta L., Riva I., Katsanos A. et al.(2015).Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressare. Clinical Ophthalmology, 9: 633-643.
  9. Sezgin Akcay B.I., Guney E., Bozkurt T.K. et al.(2014). Effects of Polyquaternium- and Belzankonium- Chloride-preserved travoprost on ocular surfaces: an impression citology study. J. Ocular Pharmacol. Therapeutics, 30 (7): 548-553.

[Italo Giuffre. (2017); OCULAR SURFACE AND GLAUCOMA DRUGS. Int. J. of Adv. Res. 5 (Jun). 2068-2069] (ISSN 2320-5407). www.journalijar.com

Italo Giuffre\' MD PhD
Catholic University of Rome

DOI:

Article DOI: 10.21474/IJAR01/4644      
DOI URL: https://dx.doi.org/10.21474/IJAR01/4644

Download Full Paper

Download PDF No. of Downloads: 9 | No. of Views: 76